tetano
Editor, Senior Moderator
Vaccine. 2014 Jun 12. pii: S0264-410X(14)00671-9. doi: 10.1016/j.vaccine.2014.05.015. [Epub ahead of print]
Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.
Yamin D1, Balicer RD2, Galvani AP3.
Author information
1Yale School of Public Health, 135 College Street, New Haven, CT 06510, USA. Electronic address: dan.yamin@yale.edu.
2Clalit Research Institute, Clalit Health Services, 101 Arlozorov Street, Tel Aviv, Israel.
3Yale School of Public Health, 135 College Street, New Haven, CT 06510, USA.
Abstract
Pneumonia is a common complication of influenza infection, and accounts for the majority of influenza mortality. Both the WHO and the Ministry of Health in Israel prioritize seasonal influenza vaccination primarily on the basis of age and specific co-morbidities. Here we consider whether the targeting of individuals previously infected with pneumonia for influenza vaccination would be a cost-effective addition to the current policy. We performed a retrospective cohort data analysis of 163,990 cases of pneumonia hospitalizations and 1,305,223 cases of outpatient pneumonia from 2004 to 2012, capturing more than 54% of the Israeli population. Our findings demonstrate that patients infected with pneumonia in the year prior had a substantially higher risk of becoming infected with pneumonia in subsequent years (relative risk >2.34, p<0.01). Results indicated that the benefit of targeting for influenza vaccination patients hospitalized with pneumonia in prior year would be cost-saving regardless of age. Complementing the current policy with the targeting of prior pneumonia patients would require vaccination of only a further 2.3% of the Israeli population to save additional 204-407 quality-adjusted life years (QALYs) annually at a mean price of 58-1056 USD/QALY saved. Global uncertainty analysis demonstrates that the cost-effectiveness of adding this policy is robust over a vast range of conditions. As prior pneumonia patients are currently not prioritized for influenza vaccination in Israel, nor elsewhere, this study suggests a novel supplement of current policies to improve cost-effectiveness of influenza vaccination. Future studies should use case-control study to further evaluate the effectiveness of vaccination in prior pneumonia patients.
Copyright ? 2014 Elsevier Ltd. All rights reserved.
KEYWORDS:
Cost-effectiveness; Influenza and pneumonia; Influenza vaccination
PMID:
24930716
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24930716
Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.
Yamin D1, Balicer RD2, Galvani AP3.
Author information
1Yale School of Public Health, 135 College Street, New Haven, CT 06510, USA. Electronic address: dan.yamin@yale.edu.
2Clalit Research Institute, Clalit Health Services, 101 Arlozorov Street, Tel Aviv, Israel.
3Yale School of Public Health, 135 College Street, New Haven, CT 06510, USA.
Abstract
Pneumonia is a common complication of influenza infection, and accounts for the majority of influenza mortality. Both the WHO and the Ministry of Health in Israel prioritize seasonal influenza vaccination primarily on the basis of age and specific co-morbidities. Here we consider whether the targeting of individuals previously infected with pneumonia for influenza vaccination would be a cost-effective addition to the current policy. We performed a retrospective cohort data analysis of 163,990 cases of pneumonia hospitalizations and 1,305,223 cases of outpatient pneumonia from 2004 to 2012, capturing more than 54% of the Israeli population. Our findings demonstrate that patients infected with pneumonia in the year prior had a substantially higher risk of becoming infected with pneumonia in subsequent years (relative risk >2.34, p<0.01). Results indicated that the benefit of targeting for influenza vaccination patients hospitalized with pneumonia in prior year would be cost-saving regardless of age. Complementing the current policy with the targeting of prior pneumonia patients would require vaccination of only a further 2.3% of the Israeli population to save additional 204-407 quality-adjusted life years (QALYs) annually at a mean price of 58-1056 USD/QALY saved. Global uncertainty analysis demonstrates that the cost-effectiveness of adding this policy is robust over a vast range of conditions. As prior pneumonia patients are currently not prioritized for influenza vaccination in Israel, nor elsewhere, this study suggests a novel supplement of current policies to improve cost-effectiveness of influenza vaccination. Future studies should use case-control study to further evaluate the effectiveness of vaccination in prior pneumonia patients.
Copyright ? 2014 Elsevier Ltd. All rights reserved.
KEYWORDS:
Cost-effectiveness; Influenza and pneumonia; Influenza vaccination
PMID:
24930716
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24930716